Navigation Links
In the Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Date:10/21/2013

BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Psoriasis finds that the continued uptake of Janssen's interleukin 12/23 inhibitor Stelara, which is expected to experience first-line biologic use ahead of the TNF-alpha inhibitors in the second half of the 2012-2022 forecast period, will drive sales growth. Stelara is forecast to achieve sales of $2.2 billion in 2022, accounting for 24 percent of total psoriasis sales. The launches and uptake of several emerging agents—the IL-17 inhibitors (Novartis's secukinumab, Eli Lilly's ixekizumab, and Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab) as well as Pfizer's Janus kinase inhibitor Xeljanz—will also drive sales through 2022. 

The findings also reveal that the TNF-alpha inhibitors, particularly AbbVie/Eisai's Humira, which has displaced Amgen/Stiefel/Pfizer/Takeda's Enbrel as the preferred first-line biologic, will continue to dominate as first-line biologic agents in the first half of our forecast. However, dermatologists will increasingly turn to Stelara for their biologic-naive patients, owing to the drug's favorable risk/benefit profile. T
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
2. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
4. AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
5. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
6. Flu season threat greater for people with psoriasis and psoriatic arthritis who are taking immunosuppressive drugs
7. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
10. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
11. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... -- Mandatory takeover offer for the ... the "Company") is pleased to announce the signing of ... Marijan Han žeković to acquire his 63.3% holding (equivalent ... Croatian listed pharmaceutical business.   Dechra is ... €51.4 million for the entire share capital on a ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... ... Properties - ... TRIANGLE PARK, N.C., July 22 CeNeRx BioPharma,Inc., a clinical stage company ... announced,plans to advance its lead candidate Tyrima(TM) into Phase II trials for ...
... and pegylated enzyme produces significantly enhanced survival ... ... DIEGO, July 22 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... today,announced the presentation of positive pre-clinical animal efficacy data,for its ...
Cached Medicine Technology:CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5
(Date:8/3/2015)... ... August 03, 2015 , ... The ... (ICC) announce an agreement to collaborate across a wide range of initiatives ... building code knowledge among architects. , “Our combined membership, consisting of practicing design ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is ... study is led by Kenneth G. Lucas, M.D. , chief of the division ... with colleagues at Kosair Children’s Hospital and in the UofL Department ...
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... AlignLife ... which will help the continuity of care for patients at this natural health care ... the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach ...
(Date:8/1/2015)... ... 01, 2015 , ... The condition where veins are enlarged and gnarled is ... pain and discomfort. Those who spend a lot of time on their feet and ... is doing what it can to create awareness and provide a cure in observance ...
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
Breaking Medicine News(10 mins):Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... ARLINGTON, Va., Dec. 2 From more than 1,100 photos ... and peace, the LIFE Foundation has selected six winners in ... flickr.com. The winning photos can be viewed in a video ... . , Contestants submitted one photo and a caption ...
... , American Red Cross also ... WASHINGTON, Dec. 2 The Hewlett-Packard Company Foundation has contributed ... Red Cross disaster response. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) ... Philippine communities affected by typhoons in September and October. Other ...
... , WASHINGTON and REDMOND, Wash., Dec. 2 ... announced the companies will collaborate to give caregivers single-point access ... after patients leave the hospital and to give patients and ... Living is the first post-acute care organization to adopt Microsoft ...
... to life span in males , WEDNESDAY, Dec. 2 (HealthDay ... and other mammals and could help explain why females tend ... researchers found that mice created using two female genomes -- ... than mice created from the normal combination of a male ...
... found drinking five or more per week prior to ... (HealthDay News) -- Women who drink five or more ... increase their risk of developing diabetes during pregnancy, a ... association with other chronic metabolic problems," said study author ...
... , LONDON, Dec. ... of improved therapies to treat lifestyle disorders. In the near ... witness enhanced therapies and novel drugs to treat such conditions ... ) , New analysis from Frost & Sullivan ( http://www.pharma.frost.com ...
Cached Medicine News:Health News:Wonders of Life Photo Contest Winners Announced 2Health News:Wonders of Life Photo Contest Winners Announced 3Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 2Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 3Health News:Golden Living Kick-Starts Post-Acute Health IT with Microsoft HealthVault and Amalga UIS Connection 4Health News:Sperm Gene May Cause Men's Longevity Disadvantage 2Health News:Sugary Colas Tied to Gestational Diabetes 2Health News:Sugary Colas Tied to Gestational Diabetes 3Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 2Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: